GlassScriptPhysician profile
Abrahem Kazemi
NPI 1700383585
$155,991.10
in general payments reported to CMS, 2019-2025
31 companies · $120K in 2025
The $120K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $207 · 2022: $1,230 · 2023: $4,724 · 2024: $30K · 2025: $120K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $95K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $22K · Travel and Lodging: $12K · Education: $627 · Honoraria: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $95,037.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,440.00 |
| Food and Beverage | $21,561.56 |
| Travel and Lodging | $11,519.51 |
| Education | $627.48 |
| Honoraria | $260.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $106,792.00 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $28,309.94 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Genzyme Corporation | $4,904.96 | 2022-2025 | |
| Abbvie INC. | $2,703.85 | 2020-2025 | |
| Janssen Biotech, INC. | $2,020.09 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $1,614.89 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $1,514.64 | 2023-2025 | Dupixent, Libtayo |
| Incyte Corporation | $1,096.76 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $915.29 | 2024-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $787.37 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| Dentsply Sirona INC | $725.68 | 2023 | Implant Dentistry |
| Dermavant Sciences, INC. | $658.51 | 2022-2024 | Vtama |
| Kowa Pharmaceuticals America, INC. | $650.00 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $475.00 | 2023-2025 | |
| Pfizer INC. | $461.62 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $392.44 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $327.19 | 2022-2025 | Sotyktu |
| Ucb, INC. | $304.78 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $301.54 | 2023-2025 | Otezla, Enbrel, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $166.75 | 2023-2025 | Jublia, Duobrii, Arazlo |
| Merz North America, INC. | $146.21 | 2022-2024 | Xeomin |
| Verrica Pharmaceuticals INC. | $138.99 | 2023-2025 | Ycanth |
| Botanix Sb INC | $137.91 | 2025 | Sofdra |
| Organon LLC | $131.92 | 2025 | Vtama, Hadlima |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Strata Skin Sciences, INC. | $58.11 | 2023 | Xtrac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.62 | 2024 | Spevigo |
| Mallinckrodt Hospital Products INC. | $29.85 | 2024 | Acthar |
| Lnhc, INC | $23.97 | 2025 | Zelsuvmi |
| Ani Pharmaceuticals, INC. | $23.43 | 2025 | Veregen |
| Almirall LLC | $22.79 | 2024 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abrahem Kazemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.